Clinical Trial Update: Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate in patients with locally recurrent or metastatic dermatofibrosarcoma protuberans.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma Protuberans
• Fibrosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans | Phase 2 | Status: COMPLETED